{
    "2020-12-18": [
        [
            {
                "time": "",
                "original_text": "贝达药业：恩沙替尼计划于明年向美国FDA申报一线治疗适应症的上市申",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "恩沙替尼",
                        "FDA",
                        "一线治疗",
                        "上市申报"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "人民金融·创新药指数涨1.39% 11个创新药获批临床",
                "features": {
                    "keywords": [
                        "创新药指数",
                        "涨1.39%",
                        "创新药",
                        "获批临床"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}